Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Optimi Health

Tracked across 8 events · 96 articles · First seen Jan 26, 2026 · Last active Sep 23, 2026

Sentiment
47
Attention
4
Events
8
Relationships
8
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Business
Impact: Optimi Health completed the first 2026 production and export of MDMA and psilocybin capsules to Australia, expanding its market access for psychedelic treatments for PTSD and TRD.
Jan 26, 2026 · 6 articles
4 70
Business
Impact: Optimi Health has secured ibogaine supply and is commencing development of finished drug products, positioning itself as a key supplier in the emerging psychedelic therapy market.
Jun 08, 2026 · 14 articles
4 70
Business
Impact: Optimi Health completed its first export of psilocybin to the United Kingdom for a Phase 2 clinical trial, expanding its international market reach and solidifying its position as a vertically integrated GMP supplier of psychedelic drug products. It also completed a GMP production run of 5mg psilocybin capsules, with some earmarked for clinical research in the United States and Europe.
Jun 02, 2026 · 25 articles
4 70
Tech
Impact: Optimi Health Corp. has launched new microdose psilocybin products, expanding its product range and market reach for clinical research and therapeutic programs internationally. This development is expected to positively impact the company's revenue and market position.
Jun 16, 2026 · 11 articles
4 70
Business
Impact: Optimi Health completed its third commercial shipment of psilocybin to Australia, expanding its market presence and generating recurring revenue from the sale of its psychedelic drug products for medical use.
Jun 29, 2026 · 12 articles
2 10
Tech
Optimi Health announced plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with major depressive disorder. The trial, authorized by Canada — Health Canada, will enroll up to 200 participants…
Impact: Optimi Health is the central entity initiating the Phase 2 trial, which represents its largest clinical commitment to date and a strategic step toward potential drug registration. The trial could enhance its pipeline and market positioning, though it carries development risks and no near-term revenue.
Sep 10, 2026 · 15 articles
1 5
Business
Optimi Health announced on September 8, 2026 that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026 at the Lotte New York Palace Hotel in New…
Impact: Optimi Health is the central entity of the event, announcing its participation in the H.C. Wainwright 28th Annual Global Investment Conference and making its presentation available on demand from September 11, 2026. The event offers the company a platform to engage investors, though no financial or clinical news was disclosed.
Sep 08, 2026 · 6 articles
1 10
Business
Optimi Health, a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announced the appointment of Michael Blough, Ph.D., as its Chief Clinical Development Officer, a newly created position. Dr. Blough has worked with Optimi on…
Impact: The company made the appointment to strengthen its clinical development capabilities ahead of planned Phase 2 psilocybin and Phase 3 MDMA trials. The move supports its pipeline but has limited near-term financial impact.
Sep 22, 2026 · 7 articles
Dane Stevens ↔ Optimi Health
Dane Stevens ceo ↔ Optimi Health Dane Stevens is the Chief Executive Officer and Co-Founder of Optimi Health, a c
Australia ↔ Optimi Health
Australia ↔ Optimi Health
Canada ↔ Optimi Health
Canada ↔ Optimi Health
ERGEN INTELLIGENCE
Track Optimi Health live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.